SCHEMBL26134959

SCHEMBL26134959

CN(/N=C\c1ccc(C(F)(F)F)cc1)c1nc(-c2ccccc2)cc(-c2ccccc2)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.65
▸ KMT2A Q03164 4/20 0.65
▸ LMNA P02545 2/20 0.65
▸ GAA P10253 1/20 0.65
▸ MAPT P10636 5/20 0.54
▸ PAX8 Q06710 1/20 0.54
▸ TOP1 P11387 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ DHFR P00374 1/20 0.38
▸ KIF11 P52732 1/20 0.38
▸ MCHR1 Q99705 1/20 0.38
▸ TDP1 Q9NUW8 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ SCN9A Q15858 1/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26134951 1.00 MEN1 (0.65) MEN1KMT2ALMNAGAAMAPT
SCHEMBL26135046 1.00 MEN1 (0.65) MEN1KMT2ALMNAGAAMAPT
SCHEMBL5592951 0.84 MEN1 (0.79) MEN1KMT2ALMNAGAAMAPT
SCHEMBL26134268 0.79 MEN1 (1.00) MEN1KMT2ALMNAGAAMAPT
SCHEMBL30548101 0.79 MEN1 (1.00) MEN1KMT2ALMNAGAAMAPT
SCHEMBL24784904 0.79 MEN1 (1.00) MEN1KMT2ALMNAGAAMAPT
SCHEMBL19736310 0.79 MEN1 (1.00) MEN1KMT2ALMNAGAAMAPT
SCHEMBL30082651 0.79 MEN1 (1.00) MEN1KMT2ALMNAGAAMAPT
SCHEMBL28045548 0.77 MAPT (0.50) MEN1KMT2ALMNAGAAMAPT
SCHEMBL19736547 0.76 KMT2A (0.62) MEN1KMT2ALMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214982-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2025-07-03 — — US disclosed
EP-4499615-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY Ramot at Tel-Aviv University Ltd. (IL) 2025-02-05 — — EP disclosed
WO-2023187783-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-10-05 — — WO disclosed
WO-2023187783-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214982-A1 COMPOUNDS USABLE AS MODULATORS OF PERK ACTIVITY ATF4, ERN1, ERN2 MEN1 2680/4885KMT2A 4213/4885LMNA 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback